“This acquisition underlines our ambition to accelerate growth in advanced wound care, where we showed good organic sales growth during the second half of 2020. It is also a good fit for our strategy to establish a stronger presence in Australia and New Zealand, where we – in addition to our successful Medical Solutions operations – are also in the final phase of the acquisition of Asaleo Care,” says Magnus Groth, president and CEO of Essity.
Sorbact is a clinically established innovation for advanced wound care, which is manufactured and marketed by Abigo Medical. Essity acquired 75% of Abigo Medical in February 2020.
Sorbact is used in wound care products to prevent and treat infections. It does this using a natural mode of action that binds bacteria and fungi. Sorbact does not contain antiseptics or other toxic substances, which is positive for both the patient and the environment.